Physician profile
Christopher Thompson
NPI 1548234842
$3,712.61
in general payments reported to CMS, 2019-2025
24 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $530 · 2021: $477 · 2022: $429 · 2023: $657 · 2024: $760 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,643.37 | 2022-2025 | Propel, Nuvent, Stealthstation S8 Platform |
| Acclarent, INC | $828.93 | 2019-2022 | |
| Intersect Ent, INC. | $266.67 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $209.67 | 2021-2024 | Dupixent |
| Prugen, INC. Pharmaceuticals | $88.30 | 2020 | |
| Glaxosmithkline, LLC. | $88.03 | 2021-2025 | Nucala |
| Aerin Medical INC. | $80.92 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $79.02 | 2021-2024 | |
| Optinose US, INC. | $59.31 | 2019-2025 | |
| Stryker Corporation | $53.11 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $48.44 | 2022 | |
| Biocryst US Sales Co., LLC | $37.00 | 2023-2024 | Orladeyo |
| Inspire Medical Systems, INC. | $32.39 | 2025 | Inspire |
| Neurent Medical Limited | $26.15 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Pfizer INC. | $24.41 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.39 | 2021 | |
| Grifols USA, LLC | $19.25 | 2023 | Prolastin-C Liquid |
| Genzyme Corporation | $18.14 | 2024 | |
| Circassia INC. | $17.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2024 | Eohilia |
| Amgen INC. | $15.81 | 2022 | |
| Kaleo, INC. | $14.71 | 2022 | |
| Covis Pharma Gmbh | $12.75 | 2023 | |
| Olympus America INC. | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.